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While subunit vaccines have shown partial efficacy in
clinical trials, radiation-attenuated sporozoites (RAS)
remain the ‘‘gold standard’’ for sterilizing protection
against Plasmodium infection in human vaccinees.
The variability in immunogenicity and replication
introduced by the extensive, random DNA damage
necessary to generate RAS could be overcome by
genetically attenuated parasites (GAP) designed via
gene deletion to arrest at defined points during
liver-stage development. Here, we demonstrate the
principle that late liver stage-arresting GAP induce
larger and broader CD8 T cell responses that provide
superior protection in inbred and outbred mice
compared to RAS or early-arresting GAP immuniza-
tions. Late liver stage-arresting GAP also engender
high levels of cross-stage and cross-species protec-
tion and complete protection when administered
by translationally relevant intradermal or subcuta-
neous routes. Collectively, our results underscore
the potential utility of late liver stage-arresting GAP
as broadly protective next-generation live-attenu-
ated malaria vaccines and support their potential as
a powerful model for identifying antigens to generate
cross-stage protection.
INTRODUCTION
Malaria is a devastating disease caused by Plasmodium infec-
tion that impacts nearly 40% of the world’s population. Three
hundred million new cases and more than 750,000 malaria-
related deaths are reported annually (World Health Organization,
2010). The enormity of this public health crisis underscores the
need for novel interventions, such as efficacious vaccines, to
combat human infection and break the transmission cycle of
malaria.Cell HPlasmodium infection occurs when sporozoites are trans-
mitted by infected Anopheles mosquitoes. After deposition in
the dermis, sporozoites transit to the liver where they replicate
and differentiate in hepatocytes over a period of 2–3 days
in rodents or 6–10 days in humans when exoerythrocytic
merozoites are released, infect red blood cells, and initiate the
erythrocytic replication cycle that drives the clinical manifesta-
tions of malaria (Kappe et al., 2010; Me´nard et al., 2008). Halting
Plasmodium infection during the clinically silent liver stage repre-
sents an attractive goal of antimalarial vaccination (Hill et al.,
2010; Kappe et al., 2010). However, and despite decades of
effort, currently there are no licensed antimalarial vaccines and
the most promising pre-erythrocytic subunit vaccine candidate
(RTS,S) has proven only partially effective in clinical trials (Aide
et al., 2010; Cohen et al., 2010; Greenwood, 2011).
On the other hand, it has been known for many years that
vaccination with radiation-attenuated sporozoites (RAS) induces
sterilizing liver-stage-specific immunity in rodents (Nussenzweig
et al., 1967), humans (Clyde, 1975; Hoffman et al., 2002), and
nonhuman primates (reviewed in Hafalla et al., 2006). RAS para-
sites, attenuated via random DNA damage, undergo intrahepa-
tocytic developmental arrest at the onset of replication. In
rodents and nonhuman primates, RAS-induced protection is
largely mediated by CD8 T cells, with activity directed against
Plasmodium-infected hepatocytes (Hafalla et al., 2006; Krzych
and Schwenk, 2005; Overstreet et al., 2008; Tsuji, 2010). Despite
the efficacy of RAS vaccination, this approach has yet to be
translated into a licensed vaccine. Logistical hurdles aside, one
major concern relevant to translating RAS vaccination to the
clinic involves the necessity to attenuate Plasmodium sporozo-
ites with a dose of radiation to induce DNA damage that is
both sufficient to prevent progression to blood-stage infection
and to maintain sporozoite infectivity and immunogenicity
(Chattopadhyay et al., 2009). Despite these issues, RAS have
recently progressed to clinical evaluation (Crompton et al., 2010).
By comparison, genetically attenuated parasites (GAP) gener-
ated by targeted gene deletion(s) are an attractive alternative
because parasites can be ‘‘designed’’ to arrest at specific
points of liver-stage development (Kappe et al., 2010). GAP
have been generated by deleting genes such as SAP1 (encodingost & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inc. 451
Table 1. Superior Induction of Protective Immunity in Outbred
Swiss Webster Mice by a P. yoelii Late Liver Stage-Arresting GAP
Vaccine
Attenuated
Sporozoite Vaccine
% Protection
Primary Memorya,b
% Protection
Secondary Memorya,c
Naı¨ve 0% (0/20) 5% (1/20)
RAS 5% (1/20) 45% (9/20)
sap1- 20% (4/20) 42% (8/19)
fabb/f- 40% (8/20)d 90% (18/20)e,f
a Protection is defined as the absence of blood-stage parasitemia
10 days after challenge with 1000 P. yoelii sporozoites. Numbers indicate
the number of protected/number of challenged3 100. More than 90% of
age-matched, naive Swiss Webster mice challenged in parallel devel-
oped blood-stage parasitemia.
bMice were challenged >80 days after a single immunization with 20,000
attenuated sporozoites. Data are cumulative results from two separate
challenges.
cMice were challenged >60 days after a second homologous immuniza-
tion with 20,000 attenuated sporozoites. Data are cumulative results from
two separate challenges.
d p = 0.019 (Fisher’s exact test) for primary memory RAS versus fabb/f-.
e p = 0.006 (Fisher’s exact test) for secondary memory RAS versus
fabb/f-.
f p = 0.002 (Fisher’s exact test) for secondary memory sap1- versus
fabb/f-.
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GAP-Induced T Cell Responses and ImmunitySporozoite Asparagine-rich Protein) which lead to arrest prior to
extensive parasite replication in hepatocytes (Aly et al., 2008).
Importantly, early-arresting GAP can induce CD8 T cell-depen-
dent sterilizing immunity in vaccinated mice (Aly et al., 2008;
Labaied et al., 2007; Mueller et al., 2005a, 2005b; Tarun et al.,
2007; van Dijk et al., 2005). More recently, deletion of the
FabB/F gene encoding an essential enzyme of the apicoplast-
localized type II fatty acid biosynthesis (FAS II) pathway was
shown to arrest P. yoelii (Py) at a late liver (schizont) stage
(Vaughan et al., 2009). However, it is not known whether late-
arresting fabb/f- parasites, similar to early-arresting sap1- sporo-
zoites, induce sterilizing protection against sporozoite challenge
in rodent models.
Although GAP were first described in 2005 (Mueller et al.,
2005b), no studies have directly determined if RAS-, early-, or
late-arresting GAP induce larger CD8 T cell responses or
enhanced protective immunity. Of note, Plasmodium transcrip-
tome and proteome analyses predict an increase in shared anti-
gens between late liver stage parasites and blood-stage para-
sites (Tarun et al., 2008). This suggests that immune responses
directed at the late liver stage-expressed shared antigens might
simultaneously induce protective immunity against both the liver
and blood stages of Plasmodium infection. Consistent with this
hypothesis, recent studies showed that immunization of mice
with blood-stage parasites under chloroquine cover elicited
T cell responses capable of reducing liver-stage parasite burden
after sporozoite challenge (Belnoue et al., 2008). Indeed, cross-
stage protection by immunization with a single vaccine would be
an optimal outcome to prevent malaria. Importantly, early liver
stage-arresting GAP have also recently moved into clinical eval-
uation as vaccine candidates (VanBuskirk et al., 2009; Crompton
et al., 2010). Here, we directly test the hypothesis that late-
arresting GAP elicit enhanced CD8 T cell responses and better
liver-stage immunity than early-arresting GAP or RAS. This ques-
tion is of critical importance, as the potential complexity of GAP
vaccine candidates will require priority ranking in order to
streamline their potential selection for clinical evaluation.
RESULTS
Vaccination with a Late Liver Stage-Arresting GAP
Affords Enhanced Protection in Outbred Mice
We initially tested our hypothesis with outbred mice because
they represent a stringent vaccine model that mimics the immu-
nogenetic complexity of humans and they are difficult to protect
fromPy sporozoite challenge, even aftermultiple RAS immuniza-
tions (Schmidt et al., 2010). Groups of 20 outbred SwissWebster
mice were vaccinatedwith RAS, sap1- (early liver stage-arresting
GAP) (Aly et al., 2008), or fabb/f- (late liver stage-arresting GAP)
(Vaughan et al., 2009) Py sporozoites. More than 60 days after
vaccination or homologous boost, when numerically and pheno-
typically stable memory CD8 T cell populations are established
(Kaech et al., 2002; Schmidt et al., 2010), immunized and naive
mice were challenged with virulent Py sporozoites. We observed
little protection in RAS (5%) and sap1- (20%) singly vaccinated
mice (Table 1), in which protection is defined as the absence of
blood-stage parasitemia after challenge with a stringent dose
of 1000 virulent sporozoites. In contrast, a single fabb/f- vaccina-
tion provided significantly better protection (40%) compared to452 Cell Host & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier InRAS vaccination (Table 1, p = 0.019). Although protection
against sporozoite challenge increased in all three groups after
homologous boost, fabb/f - prime-boosted outbred mice were
again significantly better protected (90%) compared to RAS-
(45%) or sap1- (42%)-immunized mice (Table 1, p = 0.006 and
p = 0.002, respectively). Thus, a late liver stage-arresting GAP
induces superior protective immunity against sporozoite chal-
lenge in outbred hosts compared to both early liver stage-
arresting GAP and RAS sporozoite vaccines.
We next examined the immunologic basis for enhanced
protection. Both RAS- and GAP-mediated protection is largely
CD8 T cell dependent (Doolan and Hoffman, 2000; Jobe et al.,
2007). Consistent with this, we found that CD8 T cells play a clear
role in protecting fabb/f--vaccinated SwissWebstermice against
sporozoite challenge (Figure S1A, available online). Therefore,
we longitudinally analyzed the magnitude of the RAS, sap1-,
and fabb/f- vaccine-induced CD8 T cell response by using our
recently described surrogate marker of activation approach
based on changes in cell surface expression of CD8a and
CD11a in responding pathogen-specific T cells (naive cells
are CD8ahiCD11alo and effector and memory cells are
CD8aloCD11ahi) (Rai et al., 2009; Schmidt et al., 2010). fabb/f-
sporozoites induced a substantially larger total CD8 T cell
response after both initial immunization and homologous boost-
ing. In particular, the total CD8 T cell response remained sig-
nificantly elevated for more than 30 days after boosting in
fabb/f--vaccinated mice compared to RAS-immunized mice
and still trended higher at 60 days after boost (Figures 1A and
1B). Of note, outbred mice immunized with early-arresting RAS
parasites exhibited at least twice the variability in the peak of
both the primary and secondary effector CD8 T cell responses
compared to late-arresting fabb/f--vaccinated mice (Figure 1C).c.
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Figure 1. P. yoelii Late Liver Stage-Arresting fabb/f-GAP Vaccination of Outbred Swiss Webster mice Generates a Larger and Less Variable
CD8 T Cell Response than Early Liver Stage-Arresting yoelii RAS or P. yoelii sap1- GAP Vaccination
(A) Representative plots showing the percent of circulating CD8 T cells that exhibit the antigen-experienced CD8aloCD11ahi phenotype before and after
immunization with 2 3 104 RAS, sap1-, or fabb/f- sporozoites. Mice were given a homologous boost of 2 3 104 sporozoites on day 91.
(B) Cumulative data showing the percent of circulating CD8 T cells that are CD8aloCD11ahi. Data (mean ± SEM) are from 40–52mice/group from two independent
experiments. Data were analyzed by one-way ANOVA (yp < 0.01; {p < 0.001).
(C) The fraction of circulating CD8 T cells that exhibit the CD8aloCD11ahi phenotype from individual mice at the peak of the primary or secondary response.
Symbols represent each individual mouse examined daily on days 5–9 after primary or booster immunization. The absolute peak CD8 T cell response for each
individual mouse (which may have occurred on a different day because of genetic variability in outbred mice) was plotted. Numbers to the right indicate the fold
difference between the highest and lowest responses within each group. See also Figure S1.
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GAP-Induced T Cell Responses and ImmunityThese data suggest the notion that additional antigens ex-
pressed by late-arresting fabb/f- parasites recruit a broader
repertoire of CD8 T cells in outbred individuals, resulting inCell Huniformly high CD8 T cell responses. Lastly, previous work has
shown correlations between Plasmodium-specific CD8 T cells
exhibiting an effector memory phenotype (CD27lo, CD43glyco+,ost & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inc. 453
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Figure 2. Late Liver Stage-Arresting P. yoelii
GAP-Vaccinated C57BL/6 Mice Have a
Larger CD8 T Cell Response that Exhibits
a More Effector Memory-like Phenotype
Compared to RAS or Early Liver Stage-
Arresting GAP Vaccination
C57BL/6 mice were vaccinated with 23 104 RAS,
sap1-, or fabb/f- sporozoites and were given
a homologous boost (2 3 104 sporozoites) on
day 111.
(A) Fraction of mice that exhibited complete
sterilizing immunity after single (1 memory) or
prime-boost (2 memory) vaccination. Mice were
challenged with 1000 virulent Py sporozoites and
protection was evaluated as described in Experi-
mental Procedures. Numbers refer to the number
of mice protected/number of mice challenged in
each group. Data are cumulative results from two
challenges (RAS and fabb/f-) or a single challenge
(sap1-). Results were analyzed by Fisher’s exact
test. p < 0.0001 for 2 memory RAS versus fabb/f-.
p < 0.0001 for 2 memory sap1- versus fabb/f-.
n.d., not determined.
(B) Cumulative data showing the percent of
circulating CD8 T cells that are CD8aloCD11ahi.
Data (mean ± SEM) are from 10–40 mice/group
from three independent experiments analyzed by
one-way ANOVA (yp < 0.01; {p < 0.001).
(C) Frequency of CD8aloCD11ahi T cells express-
ing CD27, CD43glyco, CD62L, or CD127. Data
(mean ± SEM) are from three to nine pooled
samples from two independent experiments
analyzed by one-way ANOVA followed by Tukey’s
multiple comparison test. n.s., not significant.
(D) Frequency of CD8aloCD11ahi secondary
memory T cells positive for the indicated marker.
Data (mean ± SEM) are from three to six pooled
samples from two independent experiments
analyzed by one-way ANOVA followed by Tukey’s
multiple comparison test. See also Figure S2.
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GAP-Induced T Cell Responses and ImmunityCD62Llo, and CD127lo) and protection against sporozoite chal-
lenge (Berenzon et al., 2003; Schmidt et al., 2010). However,
RAS-, sap1--, and fabb/f--induced memory CD8 T cells dis-
played similar effector memory phenotypes in Swiss Webster
mice (Figures S1B–S1D). Collectively, these data show that
enhanced protection of outbred Swiss Webster mice after
fabb/f- vaccination is associated with the induction of a larger
and less variable peak total CD8 T cell response.
Vaccination with a Late Liver Stage-Arresting GAP
Affords Enhanced Protection against Sporozoite
Challenge of Highly Susceptible C57BL/6 Mice
RAS-immunized inbred C57BL/6 mice are substantially more
difficult to protect against P. yoelii sporozoite challenge454 Cell Host & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inc.compared to RAS-immunized outbred
Swiss Webster and inbred BALB/c mice
(Doolan and Hoffman, 2000; Schmidt
et al., 2010). To extend our studies to
this stringent model, we next compared
protection by all three sporozoite
vaccines in C57BL/6 mice. More than60 days after single or prime-boost immunization with 20,000
RAS, sap1-, or fabb/f- sporozoites, groups of C57BL/6 mice
were challenged with 1000 virulent Py sporozoites. We ob-
served little protection in RAS (10%) and fabb/f- (10%) singly
vaccinated C57BL/6 mice (Figure 2A). Strikingly, however,
fabb/f- prime-boosted C57BL/6 mice were significantly better
protected (100%) compared to RAS (15%) or sap1- (0%)
prime-boosted mice (Figure 2A, p < 0.0001 and p < 0.0001,
respectively). Of note, the enhanced protection induced by
fabb/f- sporozoite vaccination of C57BL/6 mice was wholly
CD8 T cell dependent (Figure S2A). Moreover, we observed
significantly larger 1 and 2 effector (d6 and d117, respectively)
and 1 and 2 memory (d111 and d169, respectively) CD8 T cell
responses in fabb/f--vaccinated C57BL/6 mice compared to
Table 2. P. yoelii Late Liver Stage-Arresting GAP Vaccination of BALB/c Mice Affords Enhanced Protection against Homologous and
Cross-Species Sporozoite Challenge
Gene
Knockout
Primary
Immunizationa
Boostsa (Day after
Primary Immunization)
Challenge Doseb (Days after
Last Immunization) Protectionc
sap1- 1000 1000 (14) 10,000 (30) 20% (2/10)
sap1- 1000 1000 (14)/1000 (28) 10,000 (30) 100% (10/10)
fabb/f- 1000 1000 (14) 10,000 (30) 100% (10/10)d
fabb/f- 1000 1000 (14) /1000 (28) 10,000 (30) 100% (10/10)
fabb/f- 10,000 10,000 (14)/10,000 (28) 10,000 (30, 120, 210)e 100% (8/8)
fabb/f- 10,000 10,000 (14)/10,000 (28) 10,000 (14, 210) 100% (8/8)
fabb/f- 10,000 10,000 (14)/10,000 (28) 10,000 (100) 100% (5/5)
fabb/f- 10,000 10,000 (14)/10,000 (28) 10,000 (300) 100% (8/8)
fabb/f- 50,000 50,000 (14)/50,000 (28) 10,000 (210) 100% (8/8)
fabb/f- 50,000 50,000 (14)/50,000 (28) 10,000 (30) + rIgG 100% (6/6)
fabb/f- 50,000 50,000 (14)/50,000 (28) 10,000 (30) + anti-CD8 0% (0/8)
fabb/f- 50,000 i.d. 50,000 i.d. (14)/50,000 i.d. (28) 10,000 (30, 210) 100% (5/5)
fabb/f- 50,000 s.c. 50,000 s.c. (14)/50,000 s.c. (28) 10,000 (30, 210) 100% (5/5)
fabb/f- 10,000 10,000 (14)/10,000 (28) 10,000 P. berghei (150) 100% (5/5)
aMice were immunized by intravenous injection of knockout sporozoites unless otherwise noted. i.d., intradermal; s.c., subcutaneous.
bMice were challenged by intravenous injection of wild-type sporozoites.
cOne hundred percent of age-matched naive mice developed blood-stage parasitemia after challenge with virulent sporozoites.
d p = 0.0007 (Fisher’s exact test) for 1000 3 1000 (14) x 10,000 (30) challenge sap1- versus fabb/f-.
eMice protected after challenge 30 days after the last immunization were rechallenged at 120 and 210 days and 100% remained protected.
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quantitative differences, parasite-specific memory CD8 T cells in
fabb/f--vaccinated C57BL/6 mice also displayed qualitative
differences, with a larger fraction of cells exhibiting an effector
memory-like phenotype (CD27lo, CD62Llo, CD127lo) compared
to either RAS or sap1--induced cells (Figures 2C and 2D). In
contrast, there were only minor changes in the phenotype of 1
memory CD8 T cells compared to 2 memory CD8 T cells
(compare Figures 2C and 2D) within each immunization group.
Last, specific functional characteristics of memory CD8 T cells
could directly explain the differences in protection observed after
RAS, sap1-, or fabb/f- sporozoite vaccination. However, ex vivo
stimulation of CD8aloCD11ahi memory T cells from RAS, sap1-,
and fabb/f--vaccinated mice revealed no differences in IFN-g,
TNF-a, or IL-2 expression (or expression of a combination of
these cytokines) after either anti-CD33 crosslinking (Figure S2B
and S2C) or PMA + ionomycin stimulation (data not shown).
Additionally, we observed no differences in CD8 T cell degranu-
lation, a marker of cytolytic potential, among RAS, sap1-, and
fabb/f-induced CD8aloCD11ahi T cells (Figures S2D and S2E).
Collectively, these data suggest that increased protection in
fabb/f- prime-boost-vaccinated C57BL/6 mice is likely due to
the numerically larger secondary memory CD8 T cell responses
and not due to specific phenotypic or functional differences
amongmemoryCD8 T cells induced by each sporozoite vaccine.
Vaccination with a Late-Arresting GAP Engenders
Durable Cross-Species Protection and Sterilizing
Protection When Administered via Clinically Approved
Routes of Immunization
Inbred BALB/c mice have served as the major model for evalu-
ating sporozoite dose, duration of protection, routes of immuni-Cell Hzation, and cross-species protection in RAS- or GAP-induced
immunity to Plasmodium. Vaccination of BALB/c mice with
low numbers (1000) of Py GAP sporozoites revealed that
prime-boost-boost (three total) immunizations with either
sap1- or fabb/f- sporozoites resulted in complete (100%) protec-
tion. However, single boost (two total) immunizations with
fabb/f- elicited significantly enhanced protection compared to
the same vaccination with sap1- sporozoites (Table 2, p =
0.0007). Of note, fabb/f--vaccinated BALB/c mice exhibited
long-lasting (300 days) CD8 T cell-dependent sterilizing immu-
nity to high-dose challenge (10,000 sporozoites) after immuniza-
tion regimens that varied by dose, number of boosts, or
sporozoite challenge intervals (Table 2). Additionally, we also
determined that RAS, sap1-, and fabb/f- vaccination elicited
equivalent antisporozoite antibody titers in immunized mice
(data not shown). Strikingly, fabb/f- vaccination could also
engender complete (100%) sterilizing immunity against virulent
Py sporozoite challenge of BALB/c mice when administered
via two clinically approved routes of administration (intrader-
mally or subcutaneously, Table 2), which is not observed after
P. berghei (Pb-RAS) vaccination of C57BL/6 mice (three
doses—5 3 104, 2 3 104, and 2 3 104 at weekly intervals;
10,000 sporozoites challenge) (Douradinha et al., 2007; Kramer
and Vanderberg, 1975). Finally, in contrast to the handful of
studies revealing only partial cross-species protection after
multiple, high-dose Pb- or Py-RAS immunizations of inbred
mice (Douradinha et al., 2007; Purcell et al., 2008; Sedegah
et al., 2007), we observed that BALB/c mice immunized with
Py fabb/f- sporozoites exhibited 100% sterilizing cross-species
protection after challenge with 10,000 Pb sporozoites (Table 2).
Thus, fabb/f- vaccination elicited enhanced, complete, and
durable protection against both homologous and cross-speciesost & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inc. 455
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administered via two clinically approved routes of vaccination.
Enhanced Protection by a Late Liver Stage-Arresting
GAP Is Linked to Diversification of the Antigenic Targets
of the Protective CD8 T Cell Response
The BALB/c model provides an important and unique opportu-
nity to directly examine the mechanism underlying enhanced
protective immunity afforded by the late liver stage-arresting
GAP. BALB/c mice mount CD8 T cell responses against
a defined Py circumsporozoite (CS) protein epitope (CS280–288)
(Weiss et al., 1992), a sporozoite and early liver stage antigen
that is highly expressed and can serve as a target for protective
CD8 T cells (Butler et al., 2010; Weiss et al., 1992). Indeed, pro-
longed CS antigen display, detected by adoptive transfer of
CS280–288-specific CD8 T cell receptor transgenic (CS280 Tg)
cells, has been reported after RAS immunization (Cockburn
et al., 2010). Thus, one potential explanation for larger, more
protective CD8 T cell responses after fabb/f- vaccination is pro-
longed presentation of CS antigen at late time points. To
examine this possibility, we transferred naive, CFSE-labeled
CS280 Tg cells to BALB/c mice that had been vaccinated 14,
28, or 45 days earlier with RAS, sap1-, or fabb/f- sporozoites.
Analyses of CFSE dilution and accumulation of transferred
CS280 Tg cells revealed that CS antigen persisted for at least
45 days in all vaccinated mice (Figures S3A–3C). However, we
observed no significant difference in CS antigen persistence
whether mice were vaccinated with RAS, sap1- or fabb/f- sporo-
zoites (Figures S3A–3C). Thus, larger total CD8 T cell responses
and enhanced protection induced by late liver stage-arresting
GAP vaccination are not explained by differences in CS antigen
persistence.
At least two other possibilities could explain the differences in
the magnitude of the total CD8 T cell response between fabb/f--
and RAS-vaccinated mice. First, fabb/f- vaccination may simply
be a stronger stimulus, which induces higher numbers of CD8
T cells whose antigen specificity overlaps with CD8 T cells
induced by RAS. The second possibility is that new late liver
stage antigens may be expressed after vaccination with late-
arresting fabb/f- sporozoites, thus priming the expansion of addi-
tional protective CD8 T cells with nonoverlapping antigenic
specificities compared to RAS. The lack of published CD8
T cell antigens in rodent Plasmodium models precludes direct
assessment of these two potential explanations. Thus, in order
to distinguish between these possibilities we undertook two
alternative approaches. First, we transferred naive CS280 Tg
cells to naive BALB/c mice and vaccinated recipients with RAS
or fabb/f- sporozoites the next day. Consistent with our results
in SwissWebster and C57BL/6mice, we observed a significantly
larger total (CD8aloCD11ahi) CD8 T cell response in fabb/f--
vaccinated BALB/c mice compared to RAS-vaccinated mice
(Figures 3A and 3B, p < 0.0093). Importantly, the CS-specific
response, measured by enumeration of responding CS280 Tg
cells, was equivalent in fabb/f- and RAS-vaccinated mice (Fig-
ure 3C). Thus, fabb/f- vaccination does not simply drive a larger
response against shared antigens, but rather, it induces a larger
CD8 T cell response that is partially nonoverlapping (i.e., target-
ing distinct antigens) compared to the CD8 T cell response
induced by RAS vaccination. In support of this, we also observed456 Cell Host & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inconsistent alterations in the repertoire of TCR Vb chains utilized
by CD8 T cells primed by RAS versus fabb/f- sporozoites (Fig-
ure S3D), suggesting that these two sporozoite vaccines recruit
populations of CD8 T cells exhibiting partially nonoverlapping
TCR specificities.
Second, to more formally demonstrate that fabb/f- and RAS
vaccine-inducedCD8 T cells recognize antigens that are partially
nonoverlapping, we examined the ability of memory CD8 T cells
fromRAS- or fabb/f--vaccinatedmice to respond to homologous
or heterologous immunization. Sort-purified, CFSE-labeled
RAS- or fabb/f--specific memory CD8 T cells were transferred
into allelically disparate naive mice, which were subsequently
immunized with the same number of RAS or fabb/f- sporozoites
(Figure 3D, top). To control for initial antigen input during sporo-
zoite immunization (RAS or fabb/f- sporozoite dose), we trans-
ferred allelically disparate naive CS280 Tg cells into separate
naive mice given the same immunizations (Figure 3D, bottom).
All mice that received either RAS- or fabb/f--induced memory
cells or naive CS280 Tg cells were subsequently immunized
with RAS or fabb/f- sporozoites. Seven days after this subse-
quent sporozoite immunization, the fraction of CS280 Tg cells
that remained undivided was equal after RAS or fabb/f- immuni-
zation, demonstrating that sporozoite doses and early antigen
display were equivalent (Figures 3E and 3F, right panels or
bars, respectively). Furthermore, equivalent division of RAS-
specific memory cells occurred after either RAS- (homologous)
or fabb/f- (heterologous) immunization (Figure 3E, left panels or
bars, respectively), demonstrating that RAS memory cells are
specific for an overlapping pool of antigens expressed by both
RAS and fabb/f- sporozoites. In contrast, we observed signifi-
cantly more undivided fabb/f- specific memory CD8 T cells in
RAS-immunized mice compared to fabb/f--immunized mice
(Figure 3E, middle panels, and Figure 3F, bars, p = 0.007).
Thus, more fabb/f--specific memory cells remained unrespon-
sive (undivided) after heterologous RAS boost compared to
homologous fabb/f- boost. Collectively, these data demonstrate
that fabb/f- sporozoite vaccine-induced memory CD8 T cell
responses consist of a pool of cells whose antigenic specificity
is only partially overlapping with RAS-specific memory CD8
T cells.
Vaccination with Late-Arresting GAP Sporozoites
Affords Protection against Blood-Stage Challenge
Previously it has been shown that late liver stage parasites share
similar transcriptomes with blood-stage parasites (Tarun et al.,
2008), suggesting that many individual parasite proteins could
be expressed during both life cycle stages and thus serve as
antigenic targets of cross-stage (liver and blood) protective
immune responses. If true, vaccination with late liver stage-
arresting fabb/f- sporozoites could provide protection against
low-dose blood-stage parasite challenge, which is not observed
after Pb-RAS (75,000 RAS 3 1, 1000 infected red blood cell
parasite challenge [Nussenzweig et al., 1967]) or early liver
stage-arresting Pb GAP vaccinations (10,000 GAP 3 3, 10,000
infected red blood cell parasite challenge [Mueller et al.,
2005a]). To directly test this, we vaccinated groups of BALB/c
mice with fabb/f- sporozoites and challenged them intravenously
with 100 Py parasite-infected red blood cells (pRBC) 1 month
later. To assess resistance to blood-stage parasite challenge,c.
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Figure 3. Vaccination with P. yoelii fabb/f-
Sporozoites Diversifies the CD8 T Cell
Response Compared to P. yoeliiRAS Vacci-
nation
(A) One thousand Thy1.1+ CS280 TCR Tg CD8
T cells were transferred to naive Thy1.2+ BALB/c
mice 1 day before vaccination with 23 104 RAS or
fabb/f- sporozoites. Representative plots show
the fraction of CD8 T cells that are CD8aloCD11ahi
and the fraction of those that are Thy1.1+ CS280
TCR Tg CD8 T cells on day 6 after vaccination.
(B and C) Cumulative data showing the number of
CD8aloCD11ahi T cells (B) or Thy1.1+ CS280 TCR
Tg CD8 T cells (C) per spleen. Data (mean ± SD) in
(B) and (C) are from threemice per group analyzed
by unpaired Student’s t test. Data are represen-
tative of two independent experiments.
(D) RAS- or fabb/f--specific memory CD8 T cells
(Thy1.2+) or naive (Thy1.2+) CS280 TCR Tg CD8
T cells were CFSE labeled and transferred into
separate naive Thy1.1+ BALB/c mice. Recipient
mice were immunized with 23 104 RAS or fabb/f-
sporozoites. Seven days later naive or memory
CD8 T cells were assayed for dilution of CFSE.
(E) Representative plots show the gating strategy.
Numbers in histograms are the percent of RAS,
fabb/f-, or CS280 TCR Tg CD8 T cells that re-
mained undivided (CFSEhi) after vaccination with
RAS or fabb/f- sporozoites.
(F) Cumulative results showing percent of RAS-
specific (left bars), fabb/f--specific memory CD8
T cells (middle bars), or CS280 TCRTgCD8 T cells
(right bars) that remained undivided (CFSEhi) after
vaccination with RAS or fabb/f- sporozoites. Data
(mean ± SD) are from three mice per group
analyzed by unpaired Student’s t test. Data are
representative of three independent experiments.
See also Figure S3.
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GAP-Induced T Cell Responses and Immunitywe assayed peripheral blood daily for percent parasitemia.
Strikingly, fabb/f--vaccinatedmice were able to control and clear
both a nonlethal (Py 17XNL, Figure 4A) and lethal (Py YM, Fig-Cell Host & Microbe 9, 451–4ure 4B) pRBC challenge. Of note, sera
from BALB/c mice multiply vaccinated
with fabb/f- sporozoites did not exhibit
reactivity against purified recombinant
MSP-119 (Figure S4) or parasitized red
blood cells (data not shown). Thus, vacci-
nation of mice with fabb/f– late liver
stage-arresting sporozoites can also
engender cross-stage protection against
erythrocytic parasite challenge, probably
via the induction of more potent and
broadly reactive T cell responses.
DISCUSSION
Here we provide critical insight into the
induction of antimalarial immunity after
vaccination with sporozoites that repre-
sent distinct attenuation profiles. We
show that relative to vaccination withearly-arresting RAS and early-arresting sap1- GAP sporozoites,
vaccination with late liver stage-arresting fabb/f- GAP sporozo-
ites elicits higher magnitude effector and memory CD8 T cell62, June 16, 2011 ª2011 Elsevier Inc. 457
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Figure 4. Vaccination of Mice with Late Liver Stage-Arresting
fabb/f- Sporozoites Protects against Challenge with Blood-Stage
Parasites
(A and B) BALB/c mice were immunized with 1 3 105 fabb/f- sporozoites on
three occasions at 2 week intervals. Naive and immunized mice were chal-
lenged 1 month later with 100 Py XNL (nonlethal, A) or 100 Py YM (lethal, B)
blood-stage parasites. Parasitemia was measured daily. Mice in (B) were
euthanized on day 8 when parasitemia reached >60%. Data (mean ± SD) in (A)
and (B) are from five mice per group. See also Figure S4.
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GAP-Induced T Cell Responses and Immunityresponses and affords superior protection against virulent
sporozoite challenge in inbred and outbred mice. Our results
also show that late liver stage-arresting GAP elicit cross-stage
immunity against blood-stage challenge. Mechanistically, our
data link both enhanced liver-stage protection and the induction
of larger CD8 T cell responses after late liver stage-arresting
GAP vaccination to diversification of the antigenic targets of
responding CD8 T cells.
Unlike Py sap1- GAP and RAS parasites, which arrest very
early after infection, fabb/f- GAPs undergo extensive intrahepa-
tocytic schizogony with substantial cell mass increase within
the vaccinated host, yet fail to differentiate and release infectious
exoerythrocytic merozoites (Vaughan et al., 2009; model, Fig-
ure 5A). Thus, enhanced protection by fabb/f- GAP vaccination
is associated with the expression of additional parasite gene
products thatmay serve as targets of adaptive immune response
(Figure 5B). In support of this, an analysis of early–mid-stage
(24 hr) versus late (40–50 hr) liver stage parasites directly isolated
from infected mice revealed differential expression of more than
770 transcripts (Tarun et al., 2008). These observations are
consistent with our data showing that early (RAS or sap1-) and458 Cell Host & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inlate (fabb/f-) liver stage-arresting parasites elicit differential
protection and CD8 T cell responsiveness. Specifically, our
CD8 T cell analyses show that, compared to RAS, fabb/f- GAP
vaccination induces a population of CD8 T cells with partially
nonoverlapping antigenic specificity (Figure 5C). These data,
together with our fabb/f--specific memory CD8 T cell adoptive
transfer assays, show that the larger CD8 T cell response
induced after fabb/f- GAP vaccination is directed against
Plasmodium antigens not expressed by early-arresting RAS
parasites. Interestingly, and consistent with our hypothesis,
a recent study showed that CS-specific T cells dominate the
protective immune response after vaccination of rodents with
either early-arresting RAS or early-arresting uis3- or uis4- GAP
sporozoites (Kumar et al., 2009). Collectively, these data demon-
strate clear differences in the antigenic specificity of CD8 T cells
induced by early versus late liver stage-arresting whole-sporo-
zoite vaccinations (Figure 5C).
In addition, we also show that vaccination with late-arresting
fabb/f- sporozoites engenders cross-stage protection against
blood-stage challenge. This latter point is of particular interest,
as the field of pre-erythrocytic antigen discovery has mainly
focused on the identification of sporozoite and liver-stage-
specific antigens (Speake and Duffy, 2009). Although a few anti-
gens exhibiting expression in both liver and blood stage have
been investigated for cross-stage protection (Draper et al.,
2009; Gru¨ner et al., 2001a, 2001b; Preiser et al., 2004; Re´nia
et al., 1997; Robson et al., 1988; Silvie et al., 2004; Szarfman
et al., 1988), recent proteomic profiling revealed at least 375
Plasmodium proteins, which are expressed during both late liver
stage and blood stage (Vaughan and Kappe, unpublished obser-
vations). Thus, hundreds of additional candidate targets remain
to be investigated to identify the most potent antigens capable
of inducing cross-stage antimalarial immunity. In this regard,
our data highlight the clear potential of late liver stage-arresting
GAP immunizations in concert with surrogate activation marker-
based identification of Plasmodium-specific T cells as a tool
for identifying antigenic targets. Our data also suggest that
Plasmodium genes coordinately expressed during both liver
stage and blood stage may serve as important immunologic
targets for antimalarial vaccination. Last, it is important to note
that our current study evaluated more than 200 mice immunized
with 20,000–50,000 Py fabb/f- or sap1- GAP and we never
observed breakthrough blood-stage infection. Thus, exposure
of the host to infectious merosomes or merozoites cannot
explain the striking cross-stage protection we observe after
vaccination with late liver stage-arresting fabb/f- sporozoites.
Recently, both P. falciparum RAS and early liver stage-
arresting GAP have moved to evaluation in clinical trials (Cromp-
ton et al., 2010; Good andDoolan, 2010; VanBuskirk et al., 2009).
Although controversy abounds over the utility of rodent models
of antiplasmodial vaccination, it has been known for 35 years
that RAS afford sterilizing protection in humans (Clyde, 1975),
a result first shown by using rodent models (Nussenzweig
et al., 1967). Thus, the rodent model predicted the only antima-
larial vaccine ever shown to confer complete sterile protection
in humans. Herein we describe approaches and methods that
further illustrate the utility of rodent models of whole-parasite
pre-erythrocytic vaccination and that should facilitate the rapid
identification of the best candidate-attenuated sporozoitec.
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Figure 5. Model for Enhanced Protective
Immunity and Diversification of Antigenic
Targets by Parasite-Specific CD8 T Cells
Induced after Late Liver Stage-Arresting
GAP Vaccination
(A) Schematic depiction of liver-stage develop-
mental progression by early (RAS or sap1-)- and
late (fabb/f-)-arresting attenuated parasites in
rodent malaria models. Early-arresting RAS and
sap1- parasites fail to undergo extensive schi-
zogony, exhibit smaller liver-stage forms (small
parasite biomass), and have limited replication as
indicated by few parasite nuclei relative to late liver
stage-arresting fabb/f- parasites. Colors shown
within early and late-arresting liver-stage forms
depict both overlapping and nonoverlapping
expression of parasite-derived antigenic targets.
(B) Schematic depiction of changes in parasite
gene expression as a function of liver-stage
developmental progression. Yellow, blue, and red
colors indicate expression of developmental
stage-specific, parasite-derived antigenic targets,
whereas gradients of green and violet colors
represent putative antigens that are coordinately
expressed during multiple developmental stages
or the transition between stages.
(C) Relative number and altered antigenic speci-
ficity of parasite-specific CD8 T cells induced after
vaccination with early (RAS or sap1-)- versus late
(fabb/f-)-arresting attenuated sporozoites. Colors
in (C) correspond to the developmental stages in
(B) and represent the relative breadth of antigens
targeted by parasite-specific CD8 T cells after
vaccination with early versus late liver stage-arresting sporozoites. Vaccination with late-arresting fabb/f- sporozoites induces a larger population of CD8 T cells
whose antigenic specificity is only partially overlapping with CD8 T cells that arise in response to vaccination with early-arresting sporozoites.
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(P. yoelii and highly susceptible C57BL/6 or outbred mice). For
example, the surrogate activation marker approach enables
tracking of vaccine-inducedCD8 T cell responses in the absence
of defined parasite antigens or host MHC alleles. This permits
direct GAP versus RAS (or GAP versus GAP) comparisons by
using any parasite species or host strains including outbred
mice, which more closely mimic the immunogenetic complexity
of humans. In addition to outbred animals, we show that vacci-
nation with a late-arresting GAP also affords protection to even
the most difficult to protect rodents of the C57BL/6 background.
In our hands, RAS-immunized C57BL/6 mice cannot readily be
protected against Py sporozoite challenge at a memory time
point (>60 days after immunization), even after vaccination with
three doses of 20,000 RAS (Schmidt et al., 2010). Thus, our
data show that in the most stringent of rodent models, the late-
arresting GAP vaccination is vastly superior to both RAS and
an early-arresting GAP vaccination.
Second, although immunity against liver-stage Plasmodium
infection is mediated primarily by CD8 T cells, the observation
that the late liver stage-arresting fabb/f- GAP also engenders
protection against blood-stage infection raises the intriguing
possibility that substantial CD4 T cell and antibody responses
may be elicited after GAP vaccination. Indeed, in models of
subunit vaccination with well-defined blood-stage antigens or
convalescent mice, it is widely appreciated that antibodies and
CD4 T cells are the primary mechanisms that protect againstCell Hthe erythrocytic parasite cycle (Good, 2001; Taylor-Robinson,
2010). However, our preliminary studies revealed that neither
MSP-119-specific antibody responses nor serum reactivity
against Py-infected red blood cells correlated with cross-stage
protection. Interestingly, recent data suggest a potentially novel
protective role for CD8 T cells with activity against Py blood-
stage parasites (Imai et al., 2010). Thus, future studies can now
focus on understanding the cellular basis of sporozoite-induced
cross-stage protection.
Finally, our data show that late-arresting GAP are capable of
eliciting protection against sporozoite challenge when adminis-
tered via two clinically approved routes of vaccination (i.e.,
intradermally or subcutaneously). Importantly, previous work
has established that RAS vaccination only elicits complete
(100%) sterilizing immunity when administered intravenously
(Douradinha et al., 2007; Kramer and Vanderberg, 1975),
although partial protection was recently achieved in mice given
Pb RAS in the presence of a strong TLR7 agonist (Imiquimod)
when challenge occurred 15 days after the last immunization
(Voza et al., 2010). Whether the partial (or failed) efficacy in the
prior studies was due to lack of CD8 T cell induction after inoc-
ulation of RAS into the skin, muscle, or dermis remains a critically
important question. By comparison, our results showing that
a nonadjuvanted, late-arresting GAP vaccine protects 100% of
recipients at memory time points when administered via two
translatable routes of immunization suggests that RAS and
GAP may fundamentally differ with respect to their potentialost & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier Inc. 459
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GAP-Induced T Cell Responses and Immunityutility as widely deployable vaccines. It is possible that such bio-
logical differences determine whether RAS or GAP are able to
successfully migrate (or move via antigen-presenting cell traf-
ficking) from distal sites of injection to areas of T cell priming,
such as the spleen and lymph nodes (Chakravarty et al., 2007).
Thus, in the future it will be important to examine parasite distri-
bution, CD8 T cell priming, and the magnitude of the CD8 T cell
response after intradermal, intramuscular, or subcutaneous
injection of RAS or GAP sporozoites.
In summary, our data strongly suggest that the enhanced
protection observed after immunization with late liver stage-
arresting GAP results from recognition of a more diverse set of
antigens by CD8 T cells and potentially additional arms of the
immune system reacting with multistage-expressed antigens.
Although more work is required to determine whether targeting
fatty acid biosynthesis pathways (Pei et al., 2010; Vaughan
et al., 2009) or other late liver stage-expressed genes will
provide the most effective GAP for P. falciparum vaccines, our
results clearly show the principle that late-arresting GAP are
superior in inducing protective immunity. Moreover, as addi-
tional candidate genes are identified, the murine model and
surrogate activation marker approaches can be used to rapidly
investigate and prioritize the new classes of GAP candidates
for subsequent evaluation in human clinical trials. Collectively,
our data indicate that in concert with improved identification of
vaccine-induced T cells, late liver stage-arrestingGAP constitute
a powerful model for identifying late liver stage antigens that
might provide cross-stage protection and underscore the poten-
tial utility of late-arresting GAP as broadly protective second-
generation live-attenuated malaria vaccine candidates.EXPERIMENTAL PROCEDURES
Mice and Immunizations
Mice were purchased from the National Cancer Institute (Frederick, MD) and
housed at the University of Iowa animal care unit at the appropriate biosafety
level. BALB/c mice used in experiments summarized in Table 2 and Figure 4
were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed
at the Seattle Biomedical Research Institute animal care unit at the appropriate
biosafety level. The Institution Animal Care and Use Committee at both loca-
tions approved animal experiments. Mice were vaccinated as indicated in
the figure legends and tables.Parasites and Sporozoite Challenges
Anopheles stephensimosquitoes infected with wild-type Py (17XNL) were ob-
tained from New York University. A. stephensi infected with Py sap1- (Aly et al.,
2008), Py fabb/f- (Vaughan et al., 2009), or P. berghei (Pb) were generated at
Seattle Biomedical Research Institute. Wild-type Pb and Py or gene knockout
Py (sap1- and fabb/f-) sporozoites were isolated from the salivary glands of
infected A. stephensi mosquitoes. Wild-type sporozoites were radiation
attenuated by exposure to 200 Gy (20,000 rads). Naive and immunized mice
were challenged with the indicated number of wild-type Pb or Py sporozoites
i.v. Parasitized red blood cells were identified by Giemsa stain 10 days after
challenge. Protection is defined as the absence of blood-stage parasites. At
least 10 fields of >200 red blood cells were examined for each mouse to be
designated as protected.Blood-Stage Challenge
Naive and immunized mice were infected i.v. with 100 Py YM (lethal) or Py
XNL (nonlethal) blood-stage parasites. Parasitemia was checked daily until it
was undetectable. Mice were euthanized if parasitemia was >60%.460 Cell Host & Microbe 9, 451–462, June 16, 2011 ª2011 Elsevier InIdentification of Parasite-Specific CD8 T Cells
RAS, sap1-, and fabb/f- vaccine-induced CD8 T cell populations were identi-
fied by staining peripheral blood with anti-CD8a (53-6.7) (eBioscience, San
Diego, CA) and anti-CD11a (M17/4) (eBioscience) antibodies. RAS-, sap1--,
and fabb/f--specific CD8aloCD11ahi T cells were characterized by using
anti-CD43glyco (1B11) (Biolegend), anti-CD127 (SB/199) (Biologend), anti-
CD27 (LG.7F9) (eBioscience), and anti-CD62L (MEL-14) (BD Biosciences
PharMingen, San Diego, CA) antibodies. Cells were analyzed by using a BD
FACSCanto. Data were analyzed by using FlowJo software (Tree Star, Inc.,
Ashland, OR). Animals were prebled prior to vaccination to establish individual
background-circulating CD8aloCD11ahi T cell frequencies.
RAS versus fabb/f- Sporozoite-Induced CS280 TCR Tg CD8 T Cell
Responses
One thousand naive TCRTg (Thy1.1/1.2+) CD8 Tcells specific for theCS280–288
Py epitope (Cockburn et al., 2010) were transferred to BALB/c mice (Thy1.2+).
Oneday latermicewere vaccinatedwith 23104RASor fabb/f- sporozoites. Six
days later the frequency and total number of splenic RAS or fabb/f--specific
CD8aloCD11ahi T cells and CS280 TCR Tg CD8 T cells was determined.
Identification of a More Diverse CD8 T Cell Response
in fabb/f--Vaccinated Mice
BALB/c (Thy1.2) mice were vaccinated and boosted >60 days later (2 3 104
fabb/f- sporozoites for each immunization). Purified CD8aloCD11ahi T cells ob-
tained >30 days after boosting were labeled with CFSE (1 mM) and transferred
(1 3 105) into Thy1.1 BALB/c mice. Naive CFSE-labeled Thy1.1/Thy1.2+
CS280 TCR Tg CD8 T cells (5 3 105) were also transferred into naive
Thy1.1+ BALB/c mice. One day later, recipient mice were vaccinated with
23 104 RAS or fabb/f- sporozoites. Seven days after vaccination, splenocytes
from recipient mice were labeled with anti-Thy1.2-PE (OX-7) (BD Biosciences
PharMingen) followed by anti-PE microbeads (Miltenyi Biotec) and purified by
using an AutoMACS (Miltenyi Biotec). Thy1.2-enriched cell suspensions were
then stained with anti-CD8, anti-CD4, and anti-CD19. Thy1.2+ CD8aloCD11ahi
T cells were identified by gating on CD8+/Thy1.2+ cells that were CD4 and
CD19 negative. CS280 TCR Tg CD8 T cells were identified similarly and
both subsets were subsequently analyzed for dilution of CFSE.
Statistical Analysis
Data were analyzed by using Prism4 software. Specific tests of statistical
significance are detailed in figure legends and table footnotes.
SUPPLEMENTAL INFORMATION
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